8-K: Matinas BioPharma Names CEO Jabbour Interim CFO

Matinas BioPharma Holdings, Inc. announced that its CEO, Jerome D. Jabbour, will assume the interim Chief Financial Officer role following the resignation of Keith Kucinski.

Summary

• Keith Kucinski resigned from his position as Chief Financial Officer of Matinas BioPharma Holdings, Inc., effective January 17, 2026, to pursue other opportunities.
• On January 22, 2026, the board of directors appointed Jerome D. Jabbour, the company's current Chairman of the Board, President, and Chief Executive Officer, as the interim Chief Financial Officer.
• Mr. Jabbour will continue in his existing roles and will also assume the duties of the company's principal financial officer and principal accounting officer until a successor is appointed or his earlier resignation or removal.
• Mr. Jabbour, 51, has served as the company's Chief Executive Officer since March 2018, Chairman of the Board since March 2025, and President since March 2016, and is a co-founder.
• His compensatory and other material terms of employment with the company will remain unchanged in connection with this interim appointment.

Sentiment

Score: 4

Explanation: The resignation of a CFO is generally a negative event, indicating potential instability or a lack of confidence. While the interim appointment by the CEO provides continuity, it also highlights a potential strain on leadership resources and the need for a permanent solution. The 'pursue other opportunities' reason is often a generic phrase that doesn't provide specific positive context.

Positives

• The company has established an immediate interim plan for the Chief Financial Officer role, ensuring continuity in financial leadership.
• Jerome D. Jabbour, with his extensive history and familiarity with the company as CEO, President, and Chairman, is well-positioned to maintain operational stability during the transition.

Negatives

• The resignation of a Chief Financial Officer, particularly to 'pursue other opportunities,' can signal potential instability or a lack of confidence in the company's future direction.
• The CEO assuming the interim CFO role could lead to an increased workload and potential dilution of focus from core strategic leadership responsibilities.

Risks

• Operational Strain: Jerome D. Jabbour's expanded responsibilities as CEO, President, Chairman, and interim CFO could lead to an excessive workload, potentially impacting his effectiveness across all critical roles.
• Succession Risk: The company faces the challenge of identifying and appointing a suitable permanent Chief Financial Officer, which could be a time-consuming process and introduce uncertainty.
• Investor Perception: A key executive departure, especially without an immediate permanent replacement, may be viewed negatively by investors, potentially raising questions about the company's financial stability or strategic execution.

Future Outlook

The company will seek a successor for the Chief Financial Officer role, with Jerome D. Jabbour serving in an interim capacity until a permanent appointment is made or his earlier resignation or removal.

Industry Context

In the biotechnology and pharmaceutical sectors, executive leadership changes, particularly in key financial roles, are closely watched by investors for signs of strategic shifts or operational stability. While an interim appointment by an existing CEO can provide immediate continuity, the long-term impact depends on the company's ability to attract and integrate a permanent CFO who can drive financial strategy and investor relations effectively.

Management Changes

Stakeholder Impact

• Shareholders: May experience uncertainty regarding financial leadership and potential concerns about the company's stability or future direction.
• Employees: Could face questions about leadership stability and the company's long-term plans.
• Management Team: Jerome D. Jabbour will experience an increased workload and responsibility, potentially impacting the focus on other strategic areas.

Next Steps

• The company will initiate a search for and appoint a permanent successor to the Chief Financial Officer role.
• Jerome D. Jabbour will continue to serve as interim Chief Financial Officer until a successor is appointed or his earlier resignation or removal.

Key Dates

Recommendation

The resignation of a CFO, even with an interim replacement, introduces an element of uncertainty. While the company has an experienced CEO stepping into the interim role, the dual responsibility could strain leadership resources. Investors should hold to observe the company's progress in securing a permanent CFO and assess any potential impact on financial operations or strategic execution. This event alone does not warrant a 'sell' given the interim solution, but it's a yellow flag.

Keywords

Matinas BioPharma, MTNB, CFO resignation, interim CFO, Jerome D. Jabbour, Keith Kucinski, executive change, corporate governance, biopharma